Deva Holding AS (DEVA) – aksjekurser og nyheter

DEVA:IST

Deva Holding AS

85,85 TRY

−1,32%

(−1,15) 1 D

9. okt., 18:10:00 GMT+3 · TRY

Alle symboler

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for DEVA …

Åpne

87,35 TRY

Høy

88,30 TRY

Lav

85,15 TRY

Markedsverdi

17,17 mrd.

Snittvolum

673,14k

Volum

241,60k

52 u høy

109,30 TRY

52 u lav

57,50 TRY

EPS

−4,21 TRY

Utestående aksjer

200,02 mill.

Antall ansatte

Åpne

87,35 TRY

Høy

88,30 TRY

Lav

85,15 TRY

Markedsverdi

17,17 mrd.

Snittvolum

673,14k

Volum

241,60k

52 u høy

109,30 TRY

52 u lav

57,50 TRY

EPS

−4,21 TRY

Utestående aksjer

200,02 mill.

Antall ansatte

Relaterte aksjer

BIM Birlesik Magazalar AS

402,75 TRY

+0,44%

GENIL

Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS

4,67 TRY

+9,88%

ANGEN

Anatolia TaniveBytklj Unli Ar Ge SiveTiA

8,24 TRY

+3,26%

Nyhetssaker

Fra nettkilder og nyhetspartnere

Invezz

for 1 døgn siden

Dow stiger 423 poeng etter teknologireprise, telekomaksjer faller på SpaceX

Invezz

for 3 døgn siden

AI-boblen kan sprekke i 2027 og sende S&P 500 ned til 5 000, advarer strateg

Seeking Alpha

for 59 minutter siden

15 Years In, I've Never Seen The S&P 500 Hide So Much Damage

The Sunday Guardian

for 12 minutter siden

Dow Jones Futures Prediction: Will Dow Futures Open Higher or Lower on Monday, October 12? Check US Stock Market Outlook, Key Market Drivers & What Investors Should Know

Profil

DEVA Holding A.Ş. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements. A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas. As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia

Om Deva Holding AS

Administrerende direktør-

Ansatte3,06k

Grunnlagt22. sep. 1958

Hovedkontor-

Sektor-

Nettsteddeva.com.tr

Alle verdier i TRY	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	4,47 mrd.	5,49 mrd.	6,33 mrd.	6,00 mrd.
Varekostnad	3,02 mrd.	3,84 mrd.	4,10 mrd.	2,82 mrd.
Direkte driftskostnader	3,02 mrd.	3,84 mrd.	4,10 mrd.	2,82 mrd.
Utgifter til forskning og utvikling	264,29 mill.	174,34 mill.	361,82 mill.	480,63 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	1,30 mrd.	1,58 mrd.	1,60 mrd.	1,68 mrd.
Driftskostnader	1,55 mrd.	1,74 mrd.	1,93 mrd.	2,07 mrd.
Totale driftskostnader	4,58 mrd.	5,58 mrd.	6,03 mrd.	4,89 mrd.
Driftsinntekter	−102,14 mill.	−89,10 mill.	293,59 mill.	1,11 mrd.
Andre ikke-operasjonelle inntekter	337,87 mill.	185,09 mill.	663,10 mill.	−172,42 mill.
EBT inkludert uvanlige elementer	−137,34 mill.	−340,89 mill.	585,37 mill.	527,53 mill.
EBT uten uvanlige elementer	−137,34 mill.	−362,51 mill.	586,40 mill.	527,53 mill.
Kostnad for inntektsskatt	−116,52 mill.	1,00 mrd.	682,64 mill.	−86,52 mill.
Faktisk avgiftssats	84,84 %	−294,28 %	116,62 %	−16,40 %
Andre driftskostnader	−9,80 mill.	−11,48 mill.	−34,86 mill.	−88,91 mill.
Nettoinntekt	−20,81 mill.	−1,34 mrd.	−97,27 mill.	614,05 mill.
Netto fortjenestemargin	−0,47 %	−24,48 %	−1,54 %	10,23 %
Resultat per aksje	-	-	-	-
Rente- og investeringsinntekter	59,54 mill.	23,47 mill.	114,43 mill.	157,88 mill.
Rentekostnader	−617,63 mill.	−656,70 mill.	−542,37 mill.	−662,77 mill.
Netto rentekostnader	−558,09 mill.	−633,23 mill.	−427,95 mill.	−504,88 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	237,92 mill.	622,26 mill.	701,87 mill.	1,42 mrd.
Gevinst eller tap ved salg av eiendeler	−15,06 mill.	−15,93 mill.	−32,28 mill.	−12,59 mill.

Finance

Spør om hva som helst